Greenwich LifeSciences (GLSI) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Lyell Immunopharma (LYEL) over the past year, gaining 37.0% versus a loss of 51.6%. Over five years, GLSI leads with a -59.5% price change compared with -96.8% for LYEL. Greenwich LifeSciences is the larger company by market cap ($225.9 million vs $209.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | LYEL |
|---|---|---|
| Share price | $15.39 | $8.56 |
| Market cap | $225.90M | $209.76M |
| 1-day change | -2.53% | -0.58% |
| YTD return | -26.75% | -72.19% |
| 1-year return | +37.04% | -51.61% |
| 5-year return | -59.46% | -96.78% |
| EPS (TTM) | $-1.53 | $-12.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $45.00 |
| 52-week low | $7.78 | $8.38 |
| Distance from 52-week high | -54.87% | -80.98% |
| Analyst consensus | none | buy |
| Avg. price target upside | +270.37% | +342.52% |
| Average volume | 138.72K | 144.81K |
| Shares outstanding | 14.68M | 24.51M |
| Employees | — | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed LYEL by 88.7 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
GLSI vs LYEL FAQ
Which is bigger, Greenwich LifeSciences or Lyell Immunopharma?
Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $225.90M compared with $209.76M for Lyell Immunopharma (LYEL).
Which stock has performed better over the past year, GLSI or LYEL?
GLSI returned +37.04% over the past 12 months, compared with -51.61% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Lyell Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.